Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
DOI10.1111/J.1541-0420.2008.01009.XzbMATH Open1151.62092OpenAlexW2160921653WikidataQ80921625 ScholiaQ80921625MaRDI QIDQ3549405FDOQ3549405
Authors: Peter F. Thall, Hoang Q. Nguyen, Elihu H. Estey 
Publication date: 22 December 2008
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.1541-0420.2008.01009.x
Recommendations
- Patient-specific dose finding in phase I clinical trials
- A New Dose‐Finding Design for Bivariate Outcomes
- Patient-specific dose finding in seamless phase I/II clinical trials
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- A utility approach to individualized optimal dose selection using biomarkers
- A parsimonious personalized dose-finding model via dimension reduction
- A dose finding procedure based on the multivariate likelihood ratio test
- Clinical trials for personalized dose finding
- Dose-finding with two agents in phase I oncology trials
Bayesian designphase I clinical trialadaptive designphase I/II clinical trialbiologic agentsindividualized treatment
Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)
Cites Work
- Bayesian Measures of Model Complexity and Fit
- Dose-finding designs for HIV studies
- Correlated Binary Regression with Covariates Specific to Each Binary Observation
- Title not available (Why is that?)
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- A New Dose‐Finding Design for Bivariate Outcomes
- Title not available (Why is that?)
- Title not available (Why is that?)
- Continual reassessment method for ordered groups
- TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
- Dose-Response Models with Covariates
- A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases
Cited In (17)
- Individualized dosing for multiple ordered groups of patients
- Bayesian models and decision algorithms for complex early phase clinical trials
- Patient-specific dose finding in phase I clinical trials
- Patient-specific dose finding in seamless phase I/II clinical trials
- Optimizing the concentration and bolus of a drug delivered by continuous infusion
- Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- A utility approach to individualized optimal dose selection using biomarkers
- Learning optimal personalized treatment rules in consideration of benefit and risk: with an application to treating type 2 diabetes patients with insulin therapies
- Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
- Estimating individualized treatment rules with risk constraint
- Risk-group-specific dose finding based on an average toxicity score
- Clinical trials for personalized dose finding
- Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers
- Adaptive Bayesian compound designs for dose finding studies
- Bayesian learning of dose-response parameters from a cohort under response-guided dosing
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
This page was built for publication: Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3549405)
